Maternal and infant bone mineral density 1 year after delivery in a randomized, controlled trial of maternal Tenofovir Disoproxil Fumarate to prevent mother-to-child transmission of hepatitis B virus

Horizon

ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES

Clinical Infectious Diseases

144-146 THAILANDE 2019

fdi:010076467

ENG

Clinical Infectious Diseases

1058-4838

ISI:000485166800021

10.1093/cid/ciy982

https://www.documentation.ird.fr/hor/fdi:010076467

https://www.documentation.ird.fr/intranet/publi/depot/2019-09-10/010076467.pdf

Horizon (IRD)

In a randomized, double-blind, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) use from 28 weeks gestational age to 2 months postpartum to prevent mother-to-child transmission of hepatitis B virus, there was no significant effect of maternal TDF use on maternal or infant bone mineral density 1 year after delivery/birth. 050 ; 052 UR174 Thaïlande